-
 IGNT-Igen Technologies, Inc.
Ingen Receives First Lot of the New Oxyview-Cannula to Prepare for Initial Orders
YUCAIPA, Calif., Jun 12, 2009 (GlobeNewswire via COMTEX) -- Ingen Technologies, Inc. (Pink Sheets:IGNT) a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing ageing population and emerging markets for Home (DME), Hospital and Aviation Industries announced today that the company was notified by Legend Medical Devices that the first production sample product of the Oxyview-Cannula will arrive next week.
Mr. Bill Liang of Legend Medical Devices notified Ingen that the production samples will arrive next week. The company plans on manufacturing an immediate 10,000 Oxyview-Cannula's with first deliveries available for sale before the end of June-2009. The Oxyview is manufactured by Ingen Technologies in California-USA, and bulk product will be sent to China where Legend Medical Devices will attach and package the Oxyview to various nasal-cannulas under the Ingen-Logo and shipped back to Ingen. The company was recently issued patents in China, with pending patents in Europe, Japan, and Canada. This is in addition to the previously issued patents for the USA.
There are a recorded 23 million patients in the U.S. using home oxygen therapy, and all of them, not including hospitalized patients, use several nasal cannula's each month. There are an estimated 600 million patients worldwide that require home oxygen therapy. The current market for the nasal cannula has a cost range of $2-$6 per cannula, and is used for approximately 10 days before disposed. These current cannulas do not include a built-in flow meter. The new disposable Oxyview-Cannula will include the nasal cannula and the Ingen Oxyview flow-meter attached at a cost of $4.75. Typically the nasal cannula is replaced 3-4 times each month because it builds up bacteria and moisture. The average list price for a nasal cannula is $5.75, however. The DME provider is responsible to include the cannula along with the other oxygen equipment reimbursable at a flat monthly rate from Medicare. There are several advantages to using the new Oxyview-Cannula, inclusive of allowing the patient to be assured that they are receiving the prescribed dosage of oxygen where it is needed the most and trouble-shooting equipment problems over the phone with the oxygen supplier preventing an on-site service call. Without the Oxyview-Cannula, patients cannot confirm oxygen flow nearest to them, nor can they actually be assured that the equipment is functioning properly. "The new Oxyview-Cannula should improve home oxygen therapy and decrease costs associated to unnecessary service call," stated Chris Wirth, COO of Ingen Technologies.
The nasal cannula (NC) is a device used to deliver supplemental oxygen to a patient or person in need of extra oxygen. This device consists of a plastic tube which fits behind the ears, and a set of two prongs which are placed in the nostrils. Oxygen flows from these prongs. The nasal cannula is connected to an oxygen tank, a portable oxygen generator, or a wall connection in a hospital via a flow meter. The nasal cannula carries 1-6 liters of oxygen per minute. There are also infant or neonatal nasal cannulas which carry less than one liter per minute; these also have smaller prongs. The oxygen fraction provided to the patient ranges roughly from 24% to 35%. The nasal cannula was invented by Wilfred Jones and patented in 1949 by his employer, BOC.
The company has been selling Oxyview as an individually packaged respiratory product, and has now developed a disposable and more affordable Oxyview flow meter that will be attached and prepackaged to a variety of nasal cannula products for the 23M home oxygen patients in the USA and 600M patients worldwide. The company will sell the new Oxyview-Cannula under the Ingen logo. The potential market size for the new Oxyview-Cannula is a conservative estimate of $200M per year in the U.S. and $150M per year outside the U.S..
"As mentioned in a previous release, the new disposable Oxyview-Cannula should revolutionize the home oxygen therapy market worldwide. There is nothing else in comparison, and Ingen will sell the new nasal cannula at competitive prices starting this month. For the same price, a patient can choose to either have a nasal cannula with or without a flow-meter. I can't imagine that the patient would choose a nasal cannula without the Oxyview included," stated Scott Sand, CEO and Chairman of Ingen Technologies.
About Oxyview:
Oxyview is a proprietary medical device with U.S. issued patents that stands alone in an increasing patient home oxygen therapy market while there are 23 million patients diagnosed with chronic obstructive pulmonary disease (COPD) in the United States, according to the World Health Organization, and another 12 million patients that are undiagnosed in the U.S. COPD is the fifth leading cause of death in the US and there are 600 million COPD patients worldwide where in most cases, COPD is either the first or second leading cause of death in other countries. The majority of COPD patients require continued home oxygen therapy, which includes all of the required equipment supplied by the home (DME) provider. With the new regulations for oxygen reimbursement in the U.S., the home (DME) providers need to cut costs to stay in business. Oxyview provides a substantial savings as a result of decreasing the number of service calls for the home (DME) provider. Oxyview is a pneumatic metering device that displays oxygen flow near the patient. The Oxyview flow meter easily and quickly installs on to the oxygen tubing nearest the patient where oxygen flow matters the most. Without the Oxyview, patients cannot confirm oxygen flow, and as a result there is an increase in anxiety and the patient calls the home (DME) provider with concerns. Oxyview also allows the home (DME) provider to trouble-shoot other equipment problems over the telephone which eliminates an on-site visit with the patient. More important, the Oxyview provides the patient with more assurance that they are receiving adequate and prescribed oxygen flow. The Oxyview costs less than a single service call.
Ingen Technologies,Inc. - Home
The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.
-
Ignt/ igen technologies, inc,
Stock had great news over the weekend . This stock looks like it could havr hugh day
-
IGNT news 6/15
Ingen Expects Profitability in the Fourth Quarter 2009
On Monday June 15, 2009, 5:12 pm EDT
YUCAIPA, Calif., June 15, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News) a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing aging population and emerging markets for Home (DME), Hospital and Aviation Industries, announced today that the company expects to be profitable within the 4th quarter of this year.
The company accountants have initiated the preparation of the financial and disclosure statements for an early filing in June-2009. "Our accounting team has already begun the financial preparation for filing our May 31, 2009 Year-End statements and disclosure. This will be filed on or before the end of June-2009," stated Thomas J. Neavitt, Chief Financial officer of Ingen Technologies.
The company continues to make strong progress i.e. strengthening their intellectual property, export sales, and global distribution/OEM partnerships while introducing their new respiratory product line and reducing debt.
"Despite the economic challenges that we faced at the time we began to market our new respiratory products in 2008, we continue to make great strides to point Ingen in a direction of strong earnings and a more realistic market value. The global medical community has become aggressively responsive to the importance of Oxyview and the economical and therapeutic advantages it can offer to our ailing COPD patients worldwide. The company expects to be profitable in our upcoming fourth quarter," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
About Ingen Technologies/Oxyview:
Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. The company has also introduced the new Oxyview-Nasal Cannula in June-2009. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufactures all of its respiratory products in the United States. There are 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.
Ingen Technologies,Inc. - Home
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
Contact:
Ingen Technologies, Inc.
Chris Wirth
909-790-7180
info@ingen-tech.com
Ingen Technologies,Inc. - Home
I am not a registered broker and my signatures are of my own opinion. Make your buys and sells as you see fit, never invest more than you can afford to loose.
-
IGNT news 6/17
Ingen Opens Acquisition Possibilities During Growth Period
On Wednesday June 17, 2009, 5:51 pm EDT
YUCAIPA, Calif., June 17, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News) a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing ageing population and emerging markets for Home (DME), Hospital and Aviation Industries announced today that the Board of Directors agreed to allow the company to explore various buy out possibilities.
"Our latest news regarding the recent debt reduction and expected profitability in our coming fourth quarter has opened doors with larger and proven successful publicly traded medical companies to acquire Ingen," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
"The company management has agreed to hire an Investment Banker to explore all potential offers to acquire the company. The company would only consider a buy out based upon the value of the assets, including the increased value in the patents and intellectual property," stated Thomas J. Neavitt, Chief Financial Officer.
About Ingen/Oxyview:
Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 23 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
Ingen Technologies,Inc. - Home
The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
Contact:
Ingen Technologies, Inc.
Chris Wirth
909-790-7180
info@ingen-tech.com
Ingen Technologies,Inc. - Home
I am not a registered broker and my signatures are of my own opinion. Make your buys and sells as you see fit, never invest more than you can afford to loose.
-
IGENT-Ingen Technologies, Inc.
Ingen Opens Acquisition Possibilities During Growth Period
YUCAIPA, Calif., Jun 17, 2009 (GlobeNewswire via COMTEX) -- Ingen Technologies, Inc. (Pink Sheets:IGNT) a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing ageing population and emerging markets for Home (DME), Hospital and Aviation Industries announced today that the Board of Directors agreed to allow the company to explore various buy out possibilities.
"Our latest news regarding the recent debt reduction and expected profitability in our coming fourth quarter has opened doors with larger and proven successful publicly traded medical companies to acquire Ingen," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
"The company management has agreed to hire an Investment Banker to explore all potential offers to acquire the company. The company would only consider a buy out based upon the value of the assets, including the increased value in the patents and intellectual property," stated Thomas J. Neavitt, Chief Financial Officer.
About Ingen/Oxyview:
Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 23 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
Ingen Technologies,Inc. - Home
The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.
Safe Harbor for Forward-Looking Statements: This news release includes for
-
IGNT News
Ingen Technologies, Inc. (Pink Sheets:IGNT - News) a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing ageing population and emerging markets for Home (DME), Hospital and Aviation Industries announced today that the company increased the first shipment of Oxyview-Nasal Cannula orders from 10,000 to 62,000 units, and increased production inventory for June to 100,000 units for a revenue value of $2.8 million.
The company notified Legend Medical Devices on Wednesday of this week that the first orders will be increased from 10,000 to 62,000 units for the new Oxyview-Nasal Cannula shipment. Bill Liang, President of Legend Medical Devices has agreed to prepare a revised delivery schedule. The company has received partial shipment and will start advertising the new Oxyview-Nasal Cannula next week. The company website will be updated and this new product will be available next week.
In addition, the company has notified their Corona-California based production facility, Accent Plastics Inc., to produce another 100,000 Oxyview units. The company will produce 30,000 new Oxyview model 203A units for aviation sales and 70,000 Oxyview model 206A. The new model 203A units will provide pilots with valuable and accurate oxygen readings between 0-3 liters/minute. The company is expecting additional orders from their aviation OEM partner, Delta Technology Inc.
"There is documented demand for our Oxyview products. We are working with COPD Digest on a full page color advertisement in their next edition as a part of our ad saturation campaign. Tom Pridonoff, President of Accent Plastics and Bill Liang, President of Legend Medical Devices have been extremely helpful in keeping on track with our upcoming new production order. More important is that we have completed our funding program under the Rule 504 Registration," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
The company filed a Form D registration under Rule-504 on April 6, 2009, and has recently completed the funding program. The company was notified by Worldwide Stock Transfer on Wednesday this week that the 504 registration had reached its limit. There is no longer a 504 registration or issuance of shares under Rule 504 being implemented at this time.
About Oxyview:
Oxyview is a proprietary medical device with U.S. issued patents that stands alone in an increasing patient home oxygen therapy market while there are 23 million patients diagnosed with chronic obstructive pulmonary disease (COPD) in the United States, according to the World Health Organization, and another 12 million patients that are undiagnosed in the U.S. COPD is the fifth leading cause of death in the U.S. and there are 600 million COPD patients worldwide where in most cases, COPD is either the first or second leading cause of death in other countries. The majority of COPD patients require continued home oxygen therapy, which includes all of the required equipment supplied by the home (DME) provider. With the new regulations for oxygen reimbursement in the U.S., the home (DME) providers need to cut costs to stay in business. Oxyview provides a substantial savings as a result of decreasing the number of service calls for the home (DME) provider. Oxyview is a pneumatic metering device that displays oxygen flow near the patient. The Oxyview flow meter easily and quickly installs on to the oxygen tubing nearest the patient where oxygen flow matters the most. Without the Oxyview, patients cannot confirm oxygen flow, and as a result there is an increase in anxiety and the patient calls the home (DME) provider with concerns. Oxyview also allows the home (DME) provider to trouble-shoot other equipment problems over the telephone which eliminates an on-site visit with the patient. More important, the Oxyview provides the patient with more assurance that they are receiving adequate and prescribed oxygen flow. The Oxyview cost less than a single service call.
Ingen Technologies,Inc. - Home
The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
Contact:
Ingen Technologies, Inc.Chris Wirth909-790-7180info@ingen-tech.comwww.INGEN-TECH.COM
All my signatures are purely my opinion. Please use your own buy and sell signals and never invest in a stock you can not afford to lose money on.
-
IGNT updated video chart
All my signatures are purely my opinion. Please use your own buy and sell signals and never invest in a stock you can not afford to lose money on.
-
Ignt
IGNT-Ingen Technologies, Inc.
IGNT had a better day today closing on the plus side at .0098 up 5.38% on the day. Volume has picked up a bit in the past couple of sessions , today , just a tad over 95 million.
The chart is starting to shape up some. First, the 20 day sma has crossed the 50 day sma and that is normally a good sign. Resistance is at .012 and .0147, nothing beyond that until .02. Support at .008 and .0069.
There was a press release come out after the bell today that is very positive in my opinion.
The headline for the pr is:: “Ingen Increases Oxyview Inventory to 162,000 Units for Projected Sales Demands” and you can read the entire Pr by clicking this link:
Ingen Increases Oxyview Inventory to 162,000 Units for Projected Sales Demands - Yahoo! Finance
This is definitely a stock to keep on your radar, I am looking for more good things to come out of the company.
Chart Link: http://www.profitspi.com/stock-chart...T&ca=544746313
I am not a registered broker and my signatures are of my own opinion. Make your buys and sells as you see fit, never invest more than you can afford to loose.
-
IGNT-Ingen technologies, Inc.
Hearing this could go as high as 60% today!!! Stock is on fire-Happy Friday everyone!!
-
IGNT news 6/23
Ingen Receives 2009 Award From the United States Commerce Association for Best Medical Device Manufacturer
Press Release
Source: Ingen Technologies, Inc.
On Tuesday June 23, 2009, 4:39 pm EDT
YUCAIPA, Calif., June 23, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News) a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing ageing population and emerging markets for Home (DME), Hospital and Aviation Industries announced today that the United States Commerce Association has awarded Ingen Technologies with the 2009 Best Medical Device Manufacturer award.
Various sources of information were gathered and analyzed to choose the winners in each category. The 2009 USCA Award Program focused on quality, not quantity. Winners are determined based on the information gathered both internally by the USCA and data provided by third parties.
U.S. Commerce Association (USCA) is a Washington D.C. based organization funded by local businesses operating in towns, large and small, across America. The purpose of USCA is to promote local business through public relations, marketing and advertising. The USCA "Best of Local Business" Award Program recognizes outstanding local businesses throughout the country. Each year, the USCA identifies companies that they believe have achieved exceptional marketing success in their local community and business category. These are local companies that enhance the positive image of small business through service to their customers and community.
"I am truly committed, and I believe that Ingen and our medical products will be a very successful business in the near future. The strength and experience of our management team, and the dynamic intellectual property places this company ahead of our competition. The patients, physicians and providers like our Oxyview product," stated Scott Sand, Chief Executive Officer and Chairman of the Board.
https://www.us-ca.org/AboutUsUsca.aspx?
Press Release
About Ingen Technologies, Inc. / Oxyview:
Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
Ingen Technologies,Inc. - Home
The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
Contact:
Ingen Technologies, Inc.Chris Wirth909-790-7180info@ingen-tech.comwww.INGEN-TECH.COM
I am not a registered broker and my signatures are of my own opinion. Make your buys and sells as you see fit, never invest more than you can afford to loose.
|
Checking For Related Data... |
View Profile
View Forum Posts
Private Message
Reply With Quote
Posting Permissions
Bookmarks